PharmaDrug Enters Letter Of Intent With Licensed Dealer For Pharma Grade Cocaine

FULL DISCLOSURE: This content is sponsored by PharmaDrug Inc.

PharmaDrug Inc (CSE: PHRX) is one step closer to commercializing its biosynthetic, pharmaceutical-grade cocaine. The company as of last week has seen its subsidiary, Securedose Synthetics, sign a letter of intent with a Canadian controlled drug substance licensed dealer.

The letter of intent will enable PharmaDrug to begin full GMP-approved manufacturing once it has finalized the process development for its biosynthetic cocaine product. Technology transfer for the provisionally patented synthesis method is set to begin, in advance of a full agreement for the manufacturing and distribution of the product to support safe supply programs globally.

Once details of the formulation and novel manufacturing process are shared with the licensed dealer, it is expected that feedback will be provided on the application of the process in a commercial-scale manufacturing setting. The final manufacturing and distribution agreement is also expected to include marketing initiatives for both research-based demand as well as demand for safe supply programs.

READ: PharmaDrug Anticipates Biosynthetic Cocaine Commercial-Scale Production In As Little As 12 Months

“We are extremely excited to begin the process of partnering with a Canadian controlled drug substance licensed dealer. The partnership will enable us to prepare for the next steps in SecureDose’s forward strategic and tactical plan by preparing us for the production of a commercial batch, with an eye towards distribution opportunities in the regulated supply chain,” commented Robert Steen, CEO of PharmaDrug.

A full agreement is expected to be signed with the undisclosed licensed dealer closer to the finalization of process development and the completion of a test batch.

PharmaDrug last traded at $0.035 on the CSE.


FULL DISCLOSURE: PharmaDrug is a client of Canacom Group, the parent company of The Deep Dive. Canacom Group is currently long the equity of PharmaDrug. The author has been compensated to cover PharmaDrug on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

The Russell Will Lead the Next Market Crash!? | John Feneck

The Global Conflict Has Already Started | Bryan Cunningham

Silver Still At 90:1, What If It Snaps Back To 15:1? | Glenn Jessome – Silver Tiger

Recommended

ESGold Secures $9 Million In Non-Dilutive Funding From Ocean Partners

Altamira Gold Encounters Porphyritic Intrusive Rocks In Initial Scout Drilling At Regional Targets

Related News

PharmaDrug Engages Research Lab To Advance Patented Cocaine Synthesis Method

PharmaDrug (CSE: PHRX) has formally engaged a research lab to refine and advance the development...
Tuesday, April 16, 2024, 09:31:23 AM

Is Cocaine Turning The Tide Towards Legalization?

Switzerland is currently reevaluating its stance on drug policy as reports emerge of a groundbreaking...
Wednesday, March 20, 2024, 10:40:00 AM

PharmaDrug Subsidiary Begins Prep Work For Clinical Trial Of PD-001 For Viral Infectious Diseases

PharmaDrug (CSE: PHRX) yesterday reported that its joint venture, Sairiyo Therapeutics, has begun the process...
Friday, September 20, 2024, 08:29:02 AM

Pharmadrug Signs Five Year Supply Agreement With Canada House Wellness

Canada House Wellness (CSE: CHV) and Pharmadrug (CSE: BUZZ) jointly announced today a five year...

Thursday, October 31, 2019, 12:20:18 PM

PharmaDrug JV Submits Application For Phase 1 Clinical Trials In Australia

PharmaDrug Inc (CSE: DRUG) has seen one of its joint ventures advance to the clinical...
Wednesday, May 15, 2024, 09:17:48 AM